Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease
April 25th, 2008
Intellect Neurosciences, Inc. (BULLETIN BOARD: ILNS) , announced that it has obtained a Notice of Allowance and completed the grant requirements to obtain a European patent relating to the Company's ANTISENILIN(R) antibodies and products being developed by the Company for the treatment of Alzheimer's disease. Grant of the European patent is expected in several weeks. Other patents related to the ANTISENILIN(R) antibodies have been granted in Japan, China and elsewhere. Patent applications are pending in the United States. Intellect Neurosciences is the exclusive assignee of the ANTISENILIN(R) patents, which are based on the invention of Dr. Daniel Chain, the Company's Chairman and...
Source: Health Business Week (2008-04-25)
|
